William Blair Begins Coverage on Inari Medical (NASDAQ:NARI)

William Blair started coverage on shares of Inari Medical (NASDAQ:NARI) in a report released on Thursday, MarketBeat reports. The firm issued an outperform rating on the stock.

Several other equities research analysts have also issued reports on NARI. Wells Fargo & Company lowered their price target on shares of Inari Medical from $100.00 to $84.00 and set an overweight rating on the stock in a research note on Wednesday, May 1st. Needham & Company LLC lowered shares of Inari Medical from a buy rating to a hold rating in a research note on Thursday, July 18th. Piper Sandler lowered their price target on shares of Inari Medical from $55.00 to $50.00 and set a neutral rating on the stock in a research note on Wednesday, May 1st. Canaccord Genuity Group lowered their price target on shares of Inari Medical from $75.00 to $55.00 and set a buy rating on the stock in a research note on Wednesday, May 1st. Finally, Truist Financial lifted their price target on shares of Inari Medical from $47.00 to $60.00 and gave the company a hold rating in a research note on Tuesday, July 16th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average price target of $64.83.

Inari Medical Stock Performance

Shares of NASDAQ:NARI opened at $53.83 on Thursday. Inari Medical has a 12 month low of $36.73 and a 12 month high of $71.85. The company’s fifty day simple moving average is $49.94 and its 200 day simple moving average is $49.02.

Inari Medical (NASDAQ:NARI) last issued its quarterly earnings data on Tuesday, April 30th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.15). Inari Medical had a negative return on equity of 1.65% and a negative net margin of 4.54%. The company had revenue of $143.19 million for the quarter, compared to analyst estimates of $138.32 million. Sell-side analysts expect that Inari Medical will post -0.41 EPS for the current year.

Insider Transactions at Inari Medical

In related news, insider Thomas Tu sold 16,520 shares of Inari Medical stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $55.09, for a total transaction of $910,086.80. Following the completion of the sale, the insider now owns 313,257 shares of the company’s stock, valued at approximately $17,257,328.13. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Thomas Tu sold 16,520 shares of Inari Medical stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $55.09, for a total transaction of $910,086.80. Following the completion of the sale, the insider now owns 313,257 shares of the company’s stock, valued at approximately $17,257,328.13. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Rebecca Chambers sold 964 shares of Inari Medical stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $45.39, for a total transaction of $43,755.96. Following the sale, the director now directly owns 9,944 shares of the company’s stock, valued at approximately $451,358.16. The disclosure for this sale can be found here. Insiders have sold 261,293 shares of company stock worth $13,113,558 in the last ninety days. Insiders own 10.60% of the company’s stock.

Institutional Trading of Inari Medical

Institutional investors have recently bought and sold shares of the business. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Inari Medical in the 1st quarter valued at about $30,000. GAMMA Investing LLC boosted its holdings in Inari Medical by 164.7% in the 2nd quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock valued at $34,000 after purchasing an additional 438 shares during the period. Nisa Investment Advisors LLC boosted its holdings in Inari Medical by 83.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock valued at $46,000 after purchasing an additional 435 shares during the period. Benjamin F. Edwards & Company Inc. boosted its holdings in Inari Medical by 27.4% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,098 shares of the company’s stock valued at $71,000 after purchasing an additional 236 shares during the period. Finally, Covestor Ltd boosted its holdings in Inari Medical by 30.2% in the 1st quarter. Covestor Ltd now owns 1,619 shares of the company’s stock valued at $78,000 after purchasing an additional 376 shares during the period. Institutional investors own 90.98% of the company’s stock.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.